Funding in, findings out
For any dataset: the NCI award that paid to create it, and the awards that got a published finding out of it afterwards.
NCICCR-DLBCL
Genomic Variation in Diffuse Large B Cell Lymphomas
1 award paid to create it · 20 awards funded work that used it
1. Awards that paid to create this data
2. The dataset
3. Articles that used it (6 of 8)
- Phelan et al. · Nature · 2018347 citations
- Jain et al. · Blood · 2021244 citations
- Holmes et al. · The Journal of experimental medicine · 2020188 citations
- Shouval et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022137 citations
- Chen et al. · Cell · 202555 citations
- Li et al. · Cancer cell · 202536 citations
The best connected are shown.
4. Awards those articles were funded by (6 of 20)
- Molecular Diagnosis and Prognosis in Aggressive Lymphoma · Lisa Rimsza · FY2011–2015funded 1 of these 8 articles · also paid to create this data
- Breaking immune tolerance to Survivin in Multiple Myeloma · Frederick Locke · FY2015–2019funded 1 of these 8 articles
- Immuno-Oncology · Frederick Locke, Christine O'Connell · FY1998–2026funded 1 of these 8 articles
- Stress Pathways in Tumors Drive Global MDSC Activity and Survival through Chop · Paulo Cesar Rodriguez · FY2015–2019funded 1 of these 8 articles
- Developmental Funds · Anil K Rustgi, Andrew B Lassman · FY1985–2026funded 1 of these 8 articles
- From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma · Riccardo Dalla-Favera · FY2016–2026funded 1 of these 8 articles
The best connected are shown.
Awards that paid to create this data
Credited on the dataset's own marker paper.
| Award | Project | Evidence |
|---|---|---|
| U01CA157581 U01FY2011–2015$3.1M | Molecular Diagnosis and Prognosis in Aggressive Lymphoma | API2 |
Awards that funded work using this data
8 of 10 traced articles report an NCI award. 1 of these awards also paid to create the data - the same team publishing again on its own cohort, not a duplicated row.
| Award | Project | Articles it is credited on | Evidence |
|---|---|---|---|
| U01CA157581 U01FY2011–2015$3.1M | Molecular Diagnosis and Prognosis in Aggressive Lymphoma | API2 | |
| K23CA201594 K23FY2015–2019$821k | Breaking immune tolerance to Survivin in Multiple Myeloma | API | |
| P30CA076292 P30FY1998–2026$167.0M | Immuno-Oncology | API | |
| R01CA184185 R01FY2015–2019$1.8M | Stress Pathways in Tumors Drive Global MDSC Activity and Survival through Chop | API | |
| P30CA013696 P30FY1985–2026$278.7M | Developmental Funds | API | |
| R35CA210105 R35FY2016–2026$10.0M | From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma | API | |
| P30CA008748 P30FY1985–2026$721.1M | Cancer Center Administration | API | |
| T32CA009566 T32FY1987–2026$13.0M | Basic Medical Research Training in Oncology | API | |
| P30CA033572 P30FY1985–2026$175.3M | Leadership, Planning and Evaluation | API | |
| R01CA211614 R01FY2017–2021$2.3M | Targeting TET1 signaling to treat acute myeloid leukemia | API | |
| R01CA214965 R01FY2017–2021$2.1M | The role and mechanism of FTO in leukemogenesis and drug response | API | |
| R01CA236399 R01FY2019–2023$2.3M | The role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AML | API | |
| R01CA243386 R01FY2020–2024$2.8M | Targeting FTO to treat acute myeloid leukemia | API | |
| R01CA271497 R01FY2022–2026$2.8M | The role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemia | API | |
| R01CA280389 R01FY2023–2026$2.7M | TET2-mediated epitranscriptomic regulation in leukemia microenvironment | API | |
| R50CA211404 R50FY2016–2026$1.9M | Therapeutic insights through patient derived leukemia xenografts | API | |
| U01CA305196 U01FY2025–2026$1.9M | Mechanism and therapeutic implication of RNA-modification-mediated codon-biased translation in acute myeloid leukemia | API | |
| P01CA272295 P01FY2024–2026$14.3M | Epigenetic basis and therapeutic targeting of the unique lymphoma immunological niche | API | |
| P50CA171963 P50FY2013–2026$60.2M | Core A: Biospecimen Processing | API | |
| P01CA229100 P01FY2018–2022$20.9M | Preclinical Models and Therapeutics Core | API |
Awards that maintain or redistribute this data
Resource and center grants credited on articles that used the data. Kept out of the flow above because they pay for the pipes, not for a cohort or a finding.
| Award | Project | Evidence |
|---|---|---|
| P01CA229100 P01FY2018–2022$20.9M | Preclinical Models and Therapeutics Core | API |
| P01CA272295 P01FY2024–2026$14.3M | Epigenetic basis and therapeutic targeting of the unique lymphoma immunological niche | API |
| P30CA008748 P30FY1985–2026$721.1M | Cancer Center Administration | API |
| P30CA013696 P30FY1985–2026$278.7M | Developmental Funds | API |
| P30CA033572 P30FY1985–2026$175.3M | Leadership, Planning and Evaluation | API |
| P30CA076292 P30FY1998–2026$167.0M | Immuno-Oncology | API |
| P50CA171963 P50FY2013–2026$60.2M | Core A: Biospecimen Processing | API |
| U01CA305196 U01FY2025–2026$1.9M | Mechanism and therapeutic implication of RNA-modification-mediated codon-biased translation in acute myeloid leukemia | API |
Where the links come from
NIH RePORTER maps a PMID to the awards that reported it. On a dataset’s marker paper that gives the awards which created it; on an article that used the data, the awards which funded that use.
The two sides are not measured alike. Generation is complete: a dataset has one marker paper and every award on it is resolved. Reuse is a sample - the articles using a dataset can number in the thousands, and only the few dozen strongest are retrieved and looked up. Every award shown here funded reuse; there are more that are not shown.
How far it reaches
283 datasets have an award credited with creating them, 80 with using them, and 31 both.
What is missing
No citable accession means no traceable articles; no authoritative marker paper means no attributable generation award. Absence is a gap in the record. Methods.
Start from an award instead, and see every dataset it touches.